XARELTO KIT

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

RIVAROXABAN; RIVAROXABAN

可用日期:

BAYER INC

ATC代码:

B01AF01

INN（国际名称）:

RIVAROXABAN

剂量:

15MG; 20MG

药物剂型:

KIT

组成:

RIVAROXABAN 15MG; RIVAROXABAN 20MG

给药途径:

ORAL

每包单位数:

100

处方类型:

Prescription

治疗领域:

Direct Factor Xa Inhibitors

產品總結:

Active ingredient group (AIG) number: 0256950001; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2018-12-01

产品特点

_ _
_XARELTO_
_Product Monograph Page 1 of 97 _
PRODUCT MONOGRAPH
PR
XARELTO
®
rivaroxaban tablets
2.5 mg, 10 mg, 15 mg and 20 mg
Anticoagulant
(ATC Classification: B01AF01)
Bayer Inc.
2920 Matheson Boulevard East
Mississauga, Ontario
L4W 5R6
Canada
http://www.bayer.ca
Date of Revision:
September 18, 2018
Submission Control No: 211611

2018, Bayer Inc.
® TM see www.bayer.ca/tm-mc
All other trademarks are the property of their respective owners.
_ _
_XARELTO_
_Product Monograph Page 2 of 97 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
11
DRUG INTERACTIONS
.........................................................................................................
26
DOSAGE AND ADMINISTRATION
.....................................................................................
30
OVERDOSAGE
.......................................................................................................................
36
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 38
STORAGE AND STABILITY
.................................................................................................
45
DOSAGE FORMS, COMPOSITION AND PACKAGING
1
................................................... 45
PART II : SCIENTIFIC INFORMATION
..........................................................................
47
PHARMACEUTICAL INFORMAT